William Todd Horich

CIK: 0002117599

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (22.2%)

Position reduction

Option Exercises (M)3 (33.3%)

Derivative conversions

Awards (A)1 (11.1%)

Compensation grants

Other (G, F, J, C, D, …)3 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SUPN

SUPERNUS PHARMACEUTICALS, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

SUPN
SUPERNUS PHARMACEUTICALS, INC.
Oct 30, 2026
Award(A)
Restricted Stock Unit
Direct
100K shares-
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Mar 10, 2026
Sale(S)
Direct
4.4K shares at avg. $55.00$244K
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Mar 9, 2026
Sale(S)
Direct
4.4K shares at avg. $54.00$240K
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Mar 6, 2026
Tax Payment(F)
Direct
1.7K shares at avg. $54.73$94K
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Mar 6, 2026
Exercise(M)
Direct
2.6K shares-
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Mar 6, 2026
Tax Payment(F)
Direct
521 shares at avg. $54.73$29K
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Mar 6, 2026
Exercise(M)
Direct
1.1K shares-
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Mar 6, 2026
Tax Payment(F)
Direct
1.2K shares at avg. $54.73$67K
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Mar 6, 2026
Exercise(M)
Direct
3.8K shares-

		Type	Shares	Price		Ownership
Oct 30, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Award(A) Restricted Stock Unit	100,000	-	-	Direct
Mar 10, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Sale(S)	4,439	$55.00	$244,145	Direct
Mar 9, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Sale(S)	4,438	$54.00	$239,652	Direct
Mar 6, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Tax Payment(F)	1,718	$54.73	$94,026	Direct
Mar 6, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Exercise(M)	2,625	-	$0	Direct
Mar 6, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Tax Payment(F)	521	$54.73	$28,514	Direct
Mar 6, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Exercise(M)	1,125	-	$0	Direct
Mar 6, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Tax Payment(F)	1,216	$54.73	$66,552	Direct
Mar 6, 2026	SUPN SUPERNUS PHARMACEUTICALS, INC.	Exercise(M)	3,750	-	$0	Direct

1-9 of 9 transactions

About Horich William Todd

Horich William Todd (SEC CIK 0002117599) files insider reports with the SEC as SVP, Commercial Operations of SUPERNUS PHARMACEUTICALS, INC. (SUPN).

Signal8 holds 3 ownership filings by Horich William Todd (1 Form 3, 2 Form 4), filed between Mar 10, 2026 and Nov 2, 2026. Those filings report 9 transactions, from Mar 6, 2026 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Horich William Todd's filings is in ROCKVILLE, MD.

Recent filings by Horich William Todd

Oct 30, 2026: Grant or award of SUPN derivative securities (Form 4, code A).
Mar 10, 2026: Open-market sale of SUPN shares (Form 4, code S).
Mar 9, 2026: Open-market sale of SUPN shares (Form 4, code S).
Mar 6, 2026: Tax withholding of SUPN shares (Form 4, code F).
Mar 6, 2026: Option exercise of SUPN shares (Form 4, code M).

Other insiders filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Khattar Jack A., President, CEO
Rubin Jonathan, SVP, Chief Medical Officer
DEC TIMOTHY C, Senior Vice-President & CFO
Mottola Frank, SVP, Chief Tech. Ops. Officer
Bhatt Padmanabh P., Sr. VP of IP, CSO
Hudson Frederick M., Director

How to read Form 4 transaction codes